Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Apimeds Pharmaceuticals US, Inc. ( (APUS) ).
On July 15, 2025, Apimeds Pharmaceuticals US, Inc. announced the expansion of its leadership team with the appointment of Dr. Susan Kramer as Senior Vice President of Development and Brian Peters as Head of the ai² Division. Dr. Kramer, with over 30 years of experience in biopharmaceutical research, will oversee product development activities, while Mr. Peters will lead the strategy and launch of the ai² platform. These appointments are seen as pivotal for strengthening Apimeds’ operational leadership, enhancing clinical development capabilities for Apitox, and scaling the ai² platform, marking a significant step in the company’s growth and innovation strategy.
More about Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, an intradermally administered honeybee venom-based therapeutic. The company is targeting Apitox as a potential treatment for osteoarthritis knee pain in patients who do not respond adequately to conservative non-pharmacologic therapy and common analgesics.
Average Trading Volume: 110,400
Find detailed analytics on APUS stock on TipRanks’ Stock Analysis page.